COVID-19
Conditions
Interventions
- Clarithromycin administration group:
K-237 3 mg single dose administration under fasting
Clarithromycin 400 mg twice daily before breakfast and supper
- Rifampicin administration group:
K-237 0.3-0
Sponsors
Tanigawa Ryohei
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: (1) Subject is a healthy adult male volunteer. (2) Subject is between the ages of 18 and 45 years at the time of signing informed consent. (3) Subject has a body mass index of 17.6 to 26.4 kg/m2 at Screening.
Exclusion criteria
Exclusion criteria: (1) Subject has used a drug (including over-the-counter drug, vaccination) within 14 days before the administration of the study drug in the first treatment period, or those who need to use it during the study period. (2) Subject has received products containing St John's wort within 4 weeks before the administration of the study drug in the first treatment period. Subject has received supplements and products containing grapefruit within 14 days before the administration of the study drug in the first treatment period. (3) Subject has a current malabsorption, and those who had an operation on the gastrointestinal tract that may affect absorption (excluding appendectomy).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma pharmacokinetic parameters | — |
Contacts
Public Contact- Contact for clinical trial information
Kowa Company, Ltd.
Outcome results
None listed